In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 3, 2008, Pages 774-781

  Maruyama, Shuji ^a   Tsukada, Hideo ^b   Nishiyama, Shingo ^b   Kakiuchi, Takeharu ^b   Fukumoto, Dai ^b   Oku, Naoto ^a   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b HAMAMATSU PHOTONICS K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL 3 PIPERIDYLBENZILIC ACID C 11; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BLADDER; BLADDER PRESSURE; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LINEAR SYSTEM; MALE; NONHUMAN; OVERACTIVE BLADDER; PREDICTION; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; TOXICOKINETICS;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CARBON RADIOISOTOPES; MALE; MUSCARINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MUSCARINIC; URINARY BLADDER, OVERACTIVE;

EID: 44249115580     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.136390     Document Type: Article

References (39)

1. Abrams P (2001) Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Exp Opin Pharmacother 2:1685-1701.
2. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, and Ritchie K (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332:455-459.
3. Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3:46-53.
4. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55 (Suppl 5A):33-46.
5. Clemett D and Jarvis B (2001) Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18:277-304.
6. Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, and Roots I (2005) Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 years. BJU Int 95:346-349.
7. Flicker C, Ferris SH, and Serby M (1992) Hypersensitivity to scopolamine in the elderly. Psychopharmacology 107:437-441.
8. Flynn DD, Reever CM, and Ferrari-DiLeo G (1997) Pharmacological strategies to selectivity label and localize muscarinic receptor subtypes. Drug Dev Rev 40:104-116.
9. Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, and Honda K (2002) M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 366:97-103.
10. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, and D'Angelo K (1998) Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 46:8-13.
11. Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, and Steel M (2006) Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50:317-326.
12. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, and Ouslander JG (2005) Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 53:2195-2201.
13. Kay GG and Granville LJ (2005) Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 27:127-138.
14. Lipton RB, Kolodner K, and Wesnes K (2005) Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 173:493-498.
15. Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, et al. (2006) Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol 175:365-369.
16. Michel MC and Hegde SS (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists-a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 374:79-85.
17. Modiri AR, Alberts P, and Gillberg PG (2002) Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats. Urology 59:963-968.
18. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, and Sunderland T (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 17:215-226.
19. 123I]-I-QNB: methodological considerations. Nucl Med Biol 31:583-590.
20. Ohtake A, Ukai M, Hatanaka T, Kobayashi S, Ikeda K, Sato S, Miyata K, and Sasamata M (2004) In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 492:243-250.
21. Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, Hatanaka T, Suzuki M, Sato S, Sasamata M, et al. (2007) Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 30:54-58.
22. Oki T, Kageyama A, Takagi Y, Uchida S, and Yamada S (2007) Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol 177:766-770.
23. Oki T, Takagi Y, Inagaki S, Taketo MM, Manabe T, Matsui M, and Yamada S (2005) Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res 133:6-11.
24. Oki T, Yamada S, Tohma A, and Kimura R (2001) Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine. Biol Pharm Bull 24:491-495.
25. Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350:786-799.
26. Påhlman I, d'Argy R, and Nilvebrant L (2001) Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice. Arzneimittelforschung 51:125-133.
27. Pakulski C, Drobnik L, and Millo B (2000) Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit 6:314-318.
28. Pietzko A, Dimpfel W, Schwantes U, and Topfmeier P (1994) Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 47:337-343.
29. Scheife R and Takeda M (2005) Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27:144-153.
30. Skerjanec A (2006) The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 45:325-350.
31. Sugiyama T, Park YC, and Kurita T (1999) Oxybutynin disrupts learning and memory in the rat passive avoidance response. Urol Res 27:393-395.
32. Suzuki M, Noguchi Y, Okutsu H, Ohtake A, and Sasamata M (2007) Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol 557:154-158.
33. 11C]methyl-3-piperidyl benzilate as a potent radioligand for positron emission tomography. Appl Radiat Isot 50:521-525.
34. Todorova A, Vonderheid-Guth B, and Dimpfel W (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41:636-644.
35. 11C]4- MPB. Synapse 39:182-192.
36. Watanabe T (2007) The present conditions and the prospects of a skin application drug. Drug Delivery System 22:450-457.
37. Yamamura HI, Kuhar MJ, and Snyder SH (1974) In vivo identification of muscarinic cholinergic receptor binding in rat brain. Brain Res. 80:170-176.
38. Yamamura HI and Snyder SH (1974) Muscarinic cholinergic binding in rat brain. Proc Natl Acad Sci U S A 71:1725-1729.
39. Yokoyama O, Ishiura Y, Nakamura Y, and Ohkawa M (1996) Urodynamic effects of intravesical oxybutynin chloride in conscious rats. J Urol 155:768-771.